- Home
- REKR vs IPHA Comparison
REKR vs IPHA Comparison
Compare REKR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- IPHA
- Stock Information
- Founded
- REKR 2017
- IPHA 1999
- Country
- REKR United States
- IPHA France
- Employees
- REKR N/A
- IPHA N/A
- Industry
- REKR Telecommunications Equipment
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- REKR Telecommunications
- IPHA Health Care
- Exchange
- REKR Nasdaq
- IPHA Nasdaq
- Market Cap
- REKR 144.4M
- IPHA 148.3M
- IPO Year
- REKR N/A
- IPHA 2019
- Fundamental
- Price
- REKR $1.60
- IPHA $1.69
- Analyst Decision
- REKR Buy
- IPHA Strong Buy
- Analyst Count
- REKR 1
- IPHA 1
- Target Price
- REKR N/A
- IPHA $11.50
- AVG Volume (30 Days)
- REKR 12.0M
- IPHA 49.9K
- Earning Date
- REKR 11-14-2024
- IPHA 09-12-2024
- Dividend Yield
- REKR N/A
- IPHA N/A
- EPS Growth
- REKR N/A
- IPHA N/A
- EPS
- REKR N/A
- IPHA N/A
- Revenue
- REKR $43,817,000.00
- IPHA $36,202,722.00
- Revenue This Year
- REKR $33.40
- IPHA N/A
- Revenue Next Year
- REKR $41.09
- IPHA $101.65
- P/E Ratio
- REKR N/A
- IPHA N/A
- Revenue Growth
- REKR 44.46
- IPHA N/A
- 52 Week Low
- REKR $0.78
- IPHA $1.29
- 52 Week High
- REKR $3.78
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- REKR 54.50
- IPHA 42.95
- Support Level
- REKR $1.40
- IPHA $1.60
- Resistance Level
- REKR $1.72
- IPHA $1.87
- Average True Range (ATR)
- REKR 0.36
- IPHA 0.13
- MACD
- REKR -0.03
- IPHA -0.04
- Stochastic Oscillator
- REKR 36.66
- IPHA 16.67
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.